In vitro studies revealed that lopinavir/ritonavir and hydroxychloroquine have antiviral activity against Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there is no clinical studies on the reduction of viral load in patients with COVID-19. This study investigate whether lopinavir/ritonavir or hydroxychloroquine reduces viral load from respiratory specimen in patients with mild COVID-19.
This multicenter study is an open-labelled, randomized clinical trial for 1:1:1 ratio of
lopinavir/ritonavir, hydroxychloroquine, or control arm.
Drug: Lopinavir/ritonavir
Lopinavir / Ritonavir tablet
Other Name: Kaletra
Drug: Hydroxychloroquine sulfate
Hydroxychloroquine sulfate tablet
Other Name: Oxiklorin
Inclusion Criteria:
- confirmed mild COVID-19 (NEWS scoring system 0-4)
Exclusion Criteria:
- unable to take oral medication
- pregnancy or breast feeding
- immunocompromised patients
- creatinine clearance (CCL) < 30 mL/min
- aspartate transaminase (AST) or alanine transaminase (ALT) > 5 times Upper limit of
normal (ULN)
Asan Medical Center, University of Ulsan College of Medicine
Seoul, Korea, Republic of